Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Gardasil-9 and Cervarix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 9-10-year-old girls and boys~Exclusion Criteria:~* previously received an HPV vaccine~* immunosuppressed~* known allergy to a vaccine component

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Immunogenicity two doses of Gardasil-9 (Type: ACTIVE_COMPARATOR): Subjects will receive two doses of Gardasil-9
- Immunogenicity Cervarix and Gardasil-9 (Type: EXPERIMENTAL): Subjects will receive a dose Cervarix and a dose Gardasil-9

Based on this trial design, predict the completion outcome and termination type (if applicable).